Business
GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update
COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains Immuno-Oncology Programs Advancing ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via
About this update from Geovax Labs, Inc.
[{"type":"text","content":"COVID-19 Vaccine Designed as Single-Dose Against Multiple Strains Immuno-Oncology Programs Advancing ATLANTA, GA, March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, today announced its financial results for the year ended December 31, 2020. GeoVax’s management will host a live conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, March 24 to discuss financial results and provide a general business update. Details are provided further below. GeoVax Program Updates and Other Highlights COVID-19 Vaccine– Our SARS-CoV-2 (COVID-19) vaccine is based on our GV-MVA-VLPTM technology, which enables insertion of multiple antigen fragments, potentially allowing for broad-spectrum virus prevention. Unlike certain competitor vaccines that target only the COVID-19 spike protein, our vaccines are designed to provoke a response to multiple COVID-19 antigens, which means our vaccines could be less susceptible to viral mutations. Our vaccines are intended to be used as either a primary vaccine or to boost other COVID-19 vaccines as part of vaccination strategies to provide immunity to a range of SARS-CoV-2 variants. In January 2021, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded GeoVax a Small Business Innovative Research (SBIR) grant in support of our development of a COVID-19 vaccine. The Phase 1 grant, titled, “Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,” will support the ongoing design, construction and preclinical testing of our vaccine candidates in preparation for human clinical trials. Immuno-Oncology Program– Our cancer immunotherapy program is based on the concept of combining a tumor-associated antigen vaccine with a potent anti-tumor agent, such as an Immune Checkpoint Inhibitor (“ICI”), with the goal of achieving regression of tumor growth and development. The initial animal studies, based upon a GeoVax-MUC1 vaccine/ICI combination, have been encouraging. In February 2021, we filed a U.S. patent application, covering updates to our MVA viral vector technology to amplify an immune response to a cancer antigen via vaccination, which could strengthen our intellectual property p...